Tarceva Sales Effort Will Be Led By Genentech; OSI To Provide 25% Of Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
An amendment to the companies' 2001 Tarceva development and marketing agreement clarifies responsibilities for each party upon FDA approval of the oncologic. OSI will be responsible for manufacturing commercial supply; the company plans to outsource production to third parties.
You may also be interested in...
Tarceva Average Treatment Duration Is Approximately Four Months, OSI Says
Market opportunity for Tarceva should be evaluated based on mean duration of therapy, which is “a little over four months,” rather than median progression free survival of roughly nine weeks, company says. OSI attempts to correct investor “confusion” about commercial opportunity for the Genentech/OSI lung cancer agent.
Tarceva Average Treatment Duration Is Approximately Four Months, OSI Says
Market opportunity for Tarceva should be evaluated based on mean duration of therapy, which is “a little over four months,” rather than median progression free survival of roughly nine weeks, company says. OSI attempts to correct investor “confusion” about commercial opportunity for the Genentech/OSI lung cancer agent.
Genentech/OSI Tarceva Sales Force Hiring "Essentially Complete"
Ninety percent of new sales force hires are coming from outside the company, Genentech says. Wholesaler agreements are being finalized ahead of lung cancer agent's Jan. 30 user fee date.